SELLAS Life Sciences Group, Inc.

    Jurisdiction
    United States
    LEI
    549300VZIH50VYURLQ98
    ISIN
    US81642T2096 (SLS)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    trending_flat 50 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    2 / 7

    Profile

    SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €0.00
    Gross margin
    0.0%
    EBIT
    -€23.32M
    EBIT margin
    0.0%
    Net income
    -€22.53M
    Net margin
    0.0%

    Statement period: - (published )

    Dividends

    No dividend payouts

    Earnings Calls

    Latest earnings call: November 15, 2018

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 35K $37.68K -58K Sell

    Add to watchlist

    Notifications